The Therapeutic Age of the Neonatal Fc Receptor

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2023 Feb 2

PMID 36726033

Authors

Michal Pyzik

Lisa K Kozicky

Amit K Gandhi

Richard S Blumberg

Affiliations

Soon will be listed here.

Abstract

IgGs are essential soluble components of the adaptive immune response that evolved to protect the body from infection. Compared with other immunoglobulins, the role of IgGs is distinguished and enhanced by their high circulating levels, long half-life and ability to transfer from mother to offspring, properties that are conferred by interactions with neonatal Fc receptor (FcRn). FcRn binds to the Fc portion of IgGs in a pH-dependent manner and protects them from intracellular degradation. It also allows their transport across polarized cells that separate tissue compartments, such as the endothelium and epithelium. Further, it is becoming apparent that FcRn functions to potentiate cellular immune responses when IgGs, bound to their antigens, form IgG immune complexes. Besides the protective role of IgG, IgG autoantibodies are associated with numerous pathological conditions. As such, FcRn blockade is a novel and effective strategy to reduce circulating levels of pathogenic IgG autoantibodies and curtail IgG-mediated diseases, with several FcRn-blocking strategies on the path to therapeutic use. Here, we describe the current state of knowledge of FcRn-IgG immunobiology, with an emphasis on the functional and pathological aspects, and an overview of FcRn-targeted therapy development.

Citing Articles

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects.

Horenstein A, Faini A, Morandi F, Ortolan E, Storti P, Giuliani N Front Immunol. 2025; 16:1519300.

PMID: 40013150 PMC: 11860881. DOI: 10.3389/fimmu.2025.1519300.

The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium.

McGovern D, Jones R, Jayne D, Smith R Drugs. 2025; 85(3):325-341.

PMID: 39969779 DOI: 10.1007/s40265-024-02143-z.

Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.

Chawana T, Walsh S, Stranix-Chibanda L, Chirenje Z, Yu C, Zhang L BMC Immunol. 2025; 26(1):8.

PMID: 39966732 PMC: 11837431. DOI: 10.1186/s12865-025-00687-7.

Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties.

Seth N, Xu R, DuPrie M, Choudhury A, Sihapong S, Tyler S MAbs. 2025; 17(1):2461191.

PMID: 39936406 PMC: 11834464. DOI: 10.1080/19420862.2025.2461191.

Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain.

Fiore N, Willcox K, Dayani D, Zuberi Y, Heijnen C, Grace P Brain Behav Immun. 2025; 125:371-387.

PMID: 39870199 PMC: 11903150. DOI: 10.1016/j.bbi.2025.01.015.

References

Qiao S, Kobayashi K, Johansen F, Sollid L, Andersen J, Milford E . Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A. 2008; 105(27):9337-42. PMC: 2453734. DOI: 10.1073/pnas.0801717105. View

Guo J, Li F, Qian S, Bi D, He Q, Jin H . TGEV infection up-regulates FcRn expression via activation of NF-κB signaling. Sci Rep. 2016; 6:32154. PMC: 4995372. DOI: 10.1038/srep32154. View

Wang K, Zhu L, Sun Y, Li M, Zhao X, Cui L . Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage. Nat Commun. 2020; 11(1):4421. PMC: 7474057. DOI: 10.1038/s41467-020-18251-9. View

Yap D, Hai J, Lee P, Zhou X, Lee M, Zhang Y . Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci. 2021; 14(5):1769-1779. PMC: 8504844. DOI: 10.1111/cts.13019. View

Kim J, Tsen M, Ghetie V, Ward E . Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol. 1994; 24(3):542-8. DOI: 10.1002/eji.1830240308. View

Stapleton N, Armstrong-Fisher S, Andersen J, van der Schoot C, Porter C, Page K . Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport. Mol Immunol. 2018; 95:1-9. DOI: 10.1016/j.molimm.2018.01.006. View

Chen X, Schneewind O, Missiakas D . Engineered human antibodies for the opsonization and killing of . Proc Natl Acad Sci U S A. 2022; 119(4). PMC: 8795526. DOI: 10.1073/pnas.2114478119. View

Tao M, Morrison S . Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989; 143(8):2595-601. View

Castro-Dopico T, Clatworthy M . Mucosal IgG in inflammatory bowel disease - a question of (sub)class?. Gut Microbes. 2019; 12(1):1-9. PMC: 7524157. DOI: 10.1080/19490976.2019.1651596. View

10.

Jauniaux E, Jurkovic D, Gulbis B, Liesnard C, Lees C, Campbell S . Materno-fetal immunoglobulin transfer and passive immunity during the first trimester of human pregnancy. Hum Reprod. 1995; 10(12):3297-300. DOI: 10.1093/oxfordjournals.humrep.a135906. View

11.

Swiercz R, Mo M, Khare P, Schneider Z, Ober R, Ward E . Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption. Oncotarget. 2016; 8(2):3528-3541. PMC: 5356901. DOI: 10.18632/oncotarget.13869. View

12.

Burmeister W, Gastinel L, Simister N, BLUM M, Bjorkman P . Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature. 1994; 372(6504):336-43. DOI: 10.1038/372336a0. View

13.

Timmermand O, Orbom A, Altai M, Zedan W, Holmqvist B, Safi M . A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen. Cancers (Basel). 2021; 13(14). PMC: 8307315. DOI: 10.3390/cancers13143469. View

14.

Roopenian D, Christianson G, Sproule T, Brown A, Akilesh S, Jung N . The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003; 170(7):3528-33. DOI: 10.4049/jimmunol.170.7.3528. View

15.

Ishii-Watabe A, Saito Y, Suzuki T, Tada M, Ukaji M, Maekawa K . Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Drug Metab Pharmacokinet. 2010; 25(6):578-87. DOI: 10.2133/dmpk.dmpk-10-rg-067. View

16.

Crowley H, Alroy J, Sproule T, Roopenian D, Huber B . The MHC class I-related FcRn ameliorates murine Lyme arthritis. Int Immunol. 2006; 18(3):409-14. DOI: 10.1093/intimm/dxh380. View

17.

Bai Y, Ye L, Tesar D, Song H, Zhao D, Bjorkman P . Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci U S A. 2011; 108(45):18406-11. PMC: 3215070. DOI: 10.1073/pnas.1115348108. View

18.

West Jr A, Bjorkman P . Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry. 2000; 39(32):9698-708. DOI: 10.1021/bi000749m. View

19.

Liu X, Palaniyandi S, Zhu I, Tang J, Li W, Wu X . Human cytomegalovirus evades antibody-mediated immunity through endoplasmic reticulum-associated degradation of the FcRn receptor. Nat Commun. 2019; 10(1):3020. PMC: 6617459. DOI: 10.1038/s41467-019-10865-y. View

20.

Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B . Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2020; 96(6):e853-e865. PMC: 8105899. DOI: 10.1212/WNL.0000000000011108. View